Skin Rash - Pipeline Review, H2 2011

Description: Skin Rash - Pipeline Review, H2 2011

Summary

Global Markets Direct's, 'Skin Rash - Pipeline Review, H2 2011', provides an overview of the Skin Rash therapeutic pipeline. This report provides information on the therapeutic development for Skin Rash, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Rash. 'Skin Rash - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note:- Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Skin Rash.
- A review of the Skin Rash products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Skin Rash pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Skin Rash.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Skin Rash pipeline depth and focus of Skin Rash therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Skin Rash Overview
Therapeutics Development
An Overview of Pipeline Products for Skin Rash
Skin Rash Therapeutics under Development by Companies
Skin Rash Therapeutics under Investigation by Universities_Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Skin Rash Therapeutics - Products under Development by Companies
Skin Rash Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Skin Rash Therapeutics Development
F. Hoffmann-La Roche Ltd.
Hana Biosciences, Inc.
Skin Rash - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Menadione Topical Lotion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Doxycycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Minocycline + Clindamycin + Hydrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cetuximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Doxycycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Skin Rash Therapeutics – Drug Profile Updates
Skin Rash - Featured News
Dec 31, 2010: BioLineRx Reports Positive Results From Phase I/II Trial Of BL-5010 For Non-Surgical Removal Of Skin Lesions
Jul 08, 2010: Hana Biosciences Receives US Patent For Menadione For Prevention And Treatment Of EGFR Inhibitor Cancer Therapy-Associated Rash
Apr 12, 2010: Inhibitex Reports Results Of Interim Analysis Of Phase II Clinical Trial Of FV-100
Dec 30, 2009: Basilea Receives Complete Response Letter From FDA On Ceftobiprole For The Treatment Of Skin And Skin Structure Infections
Nov 18, 2009: Basilea's Toctino Receives Marketing Authorization In Canada
Nov 04, 2009: Cipher Pharmaceuticals Initiates A Phase III Safety Trial For CIP-ISOTRETINOIN
Sep 23, 2009: Pharming's Marketing Authorisation Application For Rhucin Validated By The European Medicines Agency
Sep 03, 2009: Pharming Submits Marketing Authorisation Application For Rhucin To The EMEA
Jul 27, 2009: Biofrontera Announces Phase II Clinical Trial Study Of BF-derm1 In Chronic Urticaria
Jun 21, 2009: BioLineRx Initiates Phase I/II Trial Of BL-5010, A Novel Formulation For The Non Surgical Removal Of Skin Lesions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Ordering: 

Order Online - [http://www.researchandmarkets.com/reports/1943840/](http://www.researchandmarkets.com/reports/1943840/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Skin Rash - Pipeline Review, H2 2011
Web Address: http://www.researchandmarkets.com/reports/1943840/
Office Code: SCD2ILQS

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Electronic (PDF) - Single User:</th>
<th>USD 500</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World